Subscribe to our Email Alerts


Mark Devlin B. Sc. (Hons) PhD GradD Drug Dev

Scientific Adviser

Mark is the Chief Executive Officer at Aculeus Therapeutics and the former Chief Scientific Officer at Amplia Therapeutics. He was the Biology Leader on the CRC Programs that delivered AMP945 and AMP886 that are now being developed by Amplia. After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark worked at the Peter MacCallum Cancer Centre between 2008 and 2018 in a number of roles for the CRC for Cancer Therapeutics (CRC), first as Head of the CRC’s Translational Cancer Biology Laboratory and later as Director of Translational Cancer Biology for the CRC. In his role as a lead scientist, Mark and his team were involved in the PRMT5 program that was licensed by the CRC to MSD, in 2016 and the Chromatin-Modifying Enzyme programs licensed to Pfizer Inc in 2018.